Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
P.M. Burger(University Medical Center Utrecht), Deepak L. Bhatt(Mount Sinai Hospital), Toni McCabe, Deborah Freeman, Dervilla McCann, Arend Mosterd(Werkgroep Cardiologische centra Nederland), Kathleen Maloney(Bill & Melinda Gates Foundation), Taryn S. Kurosawa, Jannick A N Dorresteijn(Utrecht University), Lori A Johnson, Kathleen Kelley-Garvin, Frank L.J. Visseren(University Medical Center Utrecht), Stefan Koudstaal, Fabrice M A C Martens(Deventer Ziekenhuis), Arthur Schwartzbard, Jaime Smith, Paul Alfieri, Stephanie S. Smith, Chris Dutka, Nanette Riedeman, Brenna Sprout, Denise Raychok, April Beckord, Jessica Schlinder, David Abisalih, Vinay Hosemane, Chad Kraske, Chanhsamone Syravanh, Lily Kakish, Nancy J. Hinchion, April Limcoiloc, Julie Goza, Ashley Kakish, Jennifer Chase, Marissa Tardif, Tabitha Carreira, Amy L. Little, Cindy Pau, Madeline Cassidy, Jaime Gerber, Susan Budzinski, Kylie Guy, Stacey Samuelson, Stanley E. Cobos, Joanne Ladner, Janet Guarino, Philippe Gabríel Steg(Mount Sinai Hospital), Sheila Hastings
Cited by 5
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2021|6.1k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k